ATE284403T1 - Triazolopyridazinderivate als liganden für gaba- rezeptoren - Google Patents

Triazolopyridazinderivate als liganden für gaba- rezeptoren

Info

Publication number
ATE284403T1
ATE284403T1 AT00900748T AT00900748T ATE284403T1 AT E284403 T1 ATE284403 T1 AT E284403T1 AT 00900748 T AT00900748 T AT 00900748T AT 00900748 T AT00900748 T AT 00900748T AT E284403 T1 ATE284403 T1 AT E284403T1
Authority
AT
Austria
Prior art keywords
ligands
gaba receptors
triazolopyridazine derivatives
derivatives
substituted
Prior art date
Application number
AT00900748T
Other languages
English (en)
Inventor
William Robert Carling
Piniero Jose Luis Castro
Richard Thomas Lewis
Kevin William Moore
Leslie Joseph Street
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901743.6A external-priority patent/GB9901743D0/en
Priority claimed from GBGB9901744.4A external-priority patent/GB9901744D0/en
Priority claimed from GBGB9912429.9A external-priority patent/GB9912429D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE284403T1 publication Critical patent/ATE284403T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00900748T 1999-01-27 2000-01-19 Triazolopyridazinderivate als liganden für gaba- rezeptoren ATE284403T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9901743.6A GB9901743D0 (en) 1999-01-27 1999-01-27 Therapeutic agents
GBGB9901744.4A GB9901744D0 (en) 1999-01-27 1999-01-27 Therapeutic agents
GBGB9912429.9A GB9912429D0 (en) 1999-05-27 1999-05-27 Therapeutic agents
PCT/GB2000/000183 WO2000044752A1 (en) 1999-01-27 2000-01-19 Triazolo-pyridazine derivatives as ligands for gaba receptors

Publications (1)

Publication Number Publication Date
ATE284403T1 true ATE284403T1 (de) 2004-12-15

Family

ID=27269629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00900748T ATE284403T1 (de) 1999-01-27 2000-01-19 Triazolopyridazinderivate als liganden für gaba- rezeptoren

Country Status (9)

Country Link
US (2) US6500828B1 (de)
EP (1) EP1149102B1 (de)
JP (1) JP2002535407A (de)
AT (1) ATE284403T1 (de)
AU (1) AU772947B2 (de)
CA (1) CA2359008C (de)
DE (1) DE60016566T2 (de)
ES (1) ES2232416T3 (de)
WO (1) WO2000044752A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000564D0 (en) * 2000-01-11 2000-03-01 Merck Sharp & Dohme Therapeutic agents
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
ATE371193T1 (de) * 2002-11-28 2007-09-15 Neurosearch As Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
DK2328414T3 (en) * 2008-08-29 2014-03-10 Concert Pharmaceuticals Inc Substituted triazolopyridazine derivatives
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2013170241A1 (en) * 2012-05-11 2013-11-14 Concert Pharmaceuticals, Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
JP2015516440A (ja) * 2012-05-11 2015-06-11 コンサート ファーマシューティカルズ インコーポレイテッド ７−（ｔｅｒｔ−ブチル−ｄ９）−３−（２，５−ジフルオロフェニル）−６−（（１−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）メトキシ）−［１，２，４］トリアゾロ［４，３−ｂ］ピリダジンの２型多形
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
ES2935705T3 (es) 2018-09-13 2023-03-09 Saniona As Un ligando del receptor GABA A
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
CN115837022B (zh) * 2023-02-20 2023-04-25 中山大学附属第八医院（深圳福田） 1,2,4三唑并4,3-b哒嗪衍生物在制备抗衰老药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002436B1 (ru) 1996-07-25 2002-04-25 Мерк Шарп Энд Домэ Лимитед Замещенные производные триазоло-пиридазина в качестве лигандов рецепторов гамк

Also Published As

Publication number Publication date
DE60016566D1 (de) 2005-01-13
AU3066900A (en) 2000-08-18
CA2359008A1 (en) 2000-08-03
AU772947B2 (en) 2004-05-13
US20030158203A1 (en) 2003-08-21
DE60016566T2 (de) 2005-12-15
CA2359008C (en) 2008-05-20
US6500828B1 (en) 2002-12-31
JP2002535407A (ja) 2002-10-22
ES2232416T3 (es) 2005-06-01
EP1149102B1 (de) 2004-12-08
WO2000044752A1 (en) 2000-08-03
EP1149102A1 (de) 2001-10-31

Similar Documents

Publication Publication Date Title
DE60016566D1 (de) Triazolopyridazinderivate als liganden für gaba-rezeptoren
BG104671A (en) Triazolo-pyridazine derivatives as ligands for gaba receptors
ATE270672T1 (de) Imidazopyridinderivate als liganden für gaba- rezeptoren
YU2899A (sh) Supstituisani triazolo-piridazin derivati kao ligandi za gaba receptore
PE20030432A1 (es) Derivados de imidazol-triazina como ligandos de los receptores gaba
ATE253066T1 (de) Imidazotriazinderivate als gaba rezeptor-liganden
DE60214532D1 (de) Imidazopyrimidin-derivate als liganden für gaba-rezeptoren
ATE310740T1 (de) Imidazotriazin-derivate als liganden für gaba- rezeptoren
DE69911374D1 (de) Triazolopiridazinederivate als gaba rezeptor-liganden
ATE255109T1 (de) Imidazopyridinderivate als gaba rezeptor liganden
GB0212048D0 (en) Therapeutic agents
BG108166A (en) Imidazo-pyrimidine derivatives as liigands for gaba receptors
DE69936998D1 (de) Pyrazolotriazinderivate als gaba-rezeptorliganden
WO2002002557A3 (en) 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
DE60307462D1 (de) 8-fluorimidazo(1,2-a)pyridin derivative als liganden für gaba rezeptoren
BG105152A (en) A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom
DE60325865D1 (de) Phenylpyridazin derivative als liganden für gaba-rezeptoren
PE44299A1 (es) Derivados sustituidos de triazolo-piridacina como ligandos para receptores gaba
TR200002100T2 (tr) GABA reseptörleri için ligandlar olarak triazolo-piridazin türevleri
CA2260774A1 (en) Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
JO2312B1 (en) Imidazo-pyrimidine derivatives as associative groups of JABA receptors
ATE252103T1 (de) 6-substituierte 1,2,4a,5a,8a,8b-hexahydro- und 1, 2,3,4,4a,5a,8a,8b-oktahydro-6h-pyrrolo(3',4':4, 5)furo(3,2-b)pyrid-8(7h)-on derivate und ihre verwendung zur bekämpfung von endoparasiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties